Targets for MAbs: innovative approaches for their discovery & validation, LabEx MAbImprove 6<sup>th</sup> antibody industrial symposium, June 25-26, 2018, Montpellier, France.

MAbs · 2019 · PMC6601567 · PMID 31043141

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

At the initial presentation at the 2016 European Society for Medical Oncology Congress in 2016 with about 9 months of follow-up data, highly significant improvement in progression-free survival was observed, but no real difference in OS.

also in 122,890 other papers

clearly significantno p-value reported

There are clearly significant differences between molecular characteristics of the well-characterized anti-PD-1 mAbs.

also in 513 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.